Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Continue » Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the ... after a trial patient experienced a liver injury while taking it.

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Sales of Trulicity are also being hurt by patient switches to Mounjaro ... deeper to understand whether to buy, sell or hold Lilly’s stock. Lilly’s stock has risen 14.8% so far this year ...

Shares of Eli Lilly (LLY) jumped 16% Thursday morning ... Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies Moderna Stock Jumps on New FDA COVID-19 Booster Guidelines Novavax ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster ...

The stock's rise snapped a five-day losing streak.

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that ... Pfizer said it is ending work on the pill after a patient experienced a liver injury during the drug’s trial.

This lowers patient costs but may reduce pharmaceutical ... The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”.